«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2016年第5期

页码:

593-596

栏目:

综述

出版日期:

2016-04-25

文章信息/Info

Title:

Role of β3-adrenergic receptor in the cardiovascular system via nitric oxide regulation

作者:

王 彬; 郑强荪; 牛晓琳

(第四军医大学唐都医院心血管内科， 陕西 西安 710038)

Author(s):

WANG Bin;  ZHENG Qiang-sun;  NIU Xiao-lin

(Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi, China)

关键词:

β3肾上腺素受体; 一氧化氮; 心血管系统

Keywords:

β3-AR;  nitric oxide;  cardiovascular system

分类号:

Q577

DOI:

-

文献标识码:

A

摘要:

研究发现心血管系统中β3-肾上腺素受体（β3-adrenergic receptor,β3-AR）发挥着与传统的β1-/β2-AR不同的交感神经调节作用。虽然β3-AR在心血管系统中的作用还有争议，但越来越多的证据显示其在交感神经系统过度兴奋时能够发挥类似“刹车”的心脏保护作用。β3-AR在儿茶酚胺浓度增高时激活，通过调节一氧化氮合酶影响一氧化氮（NO）生成，进而产生负性肌力作用。本文对心血管系统中β3-AR调控NO的研究进展作一综述。

Abstract:

The presence of a third β-adrenergic receptor (β3-AR) in the cardiovascular system has challenged the classical paradigm of sympathetic regulation by β1- and β2-AR. Although the role of β3-AR in the cardiovascular system remains controversial, increasing evidence suggests that β3-AR serves as a “brake” in sympathetic overstimulation. It is activated at high catecholamine concentrations, producing a negative inotropic effect via nitric oxide production, which is induced by three different nitric oxide synthases. This review summarizes the recent findings regarding the role of β3-AR as an important mediator of NO signaling in the cardiovascular system.

参考文献/References

[1] Kaumann AJ,Engelhardt S,Hein L,et al.Abolition of(-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice.Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology[J]. Naunyn Schmiedebergs Arch Pharmacol,2001,363(1):87-93.
[2]Gill RS,Cheung PY,Yu X,et al.β(3)-Adrenoceptor Antagonist SR59230A Attenuates the Imbalance of Systemic and Myocardial Oxygen Transport Induced by Dopamine in Newborn Lambs[J].Clin Med Insights Cardiol,2012,6:45-51.
[3]Tanyeri P,Buyukokuroglu ME,Mutlu O,et al.Evidence that the anxiolytic-like effects of the beta3 receptor agonist Amibegron involve serotoninergic receptor activity[J].Pharmacol Biochem Behav,2013,110: 27-32.
[4]Masutani S,Cheng HJ,Morimoto A,et al.β3-Adrenergic receptor antagonist improves exercise performance in pacing-induced heart failure[J].Am J Physiol Heart Circ Physiol, 2013,305(6):H923-H930.
[5]Maffei A,Di Pardo A,Carangi R,et al.Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation[J].Hypertension,2007,50(4):652-656.
[6]Gauthier C,Leblais V,Kobzik L,et al.The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle[J].J Clin Invest,1998,102(7):1377-1384.
[7]Zhang Z,Ding L,Jin Z,et al.Nebivolol Protects against Myocardial Infarction Injury via Stimulation of Beta 3-Adrenergic Receptors and Nitric Oxide Signaling[J].PLoS One,2014,9(5):e98179.
[8]Moens AL,Kass DA.Tetrahydrobiopterin and cardiovascular disease[J].Arterioscler Thromb Vasc Biol,2006,26(11):2439-2444.
[9]Moens AL,Leyton-Mange JS,Niu X,et al.Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the β 3-adrenoreceptor[J].J Mol Cell Cardiol,2009,47(5):576-585.
[10]Treinys R,Zablockaite D,Gendviliene V,et al.β3-Adrenergic regulation of L-type Ca2+current and force of contraction in human ventricle[J].J Membr Biol,2014,247(4):309-318.
[11]García-Prieto J,García-Ruiz JM,Sanz-Rosa D,et al.β3-adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes[J].Basic Res Cardiol,2014,109(4):422.
[12]Napp A,Brixius K,Pott C,et al.Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium[J].J Card Fail,2009,15(1):57-67.
[13]Zhang YH,Casadei B.Sub-cellular targeting of constitutive NOS in health and disease[J].J Mol Cell Cardiol,2012,52(2):341-350.
[14]Jin CZ,Jang JH,Kim HJ,et al.Myofilament Ca2+desensitization mediates positive lusitropic effect of neuronal nitric oxide synthase in left ventricular myocytes from murine hypertensive heart[J].J Mol Cell Cardiol,2013,60:107-115.
[15]Tang L,Wang H,Ziolo MT.Targeting NOS as a therapeutic approach for heart failure[J].Pharmacol Ther,2014,142(3):306-315.
[16]Zhao Q,Zeng F,Liu JB,et al.Upregulation of β3-adrenergic receptor expression in the atrium of rats with chronic heart failure[J].J Cardiovasc Pharmacol Ther,2013,18(2):133-137.
[17]Watts VL,Sepulveda FM,Cingolani OH,et al.anti-hypertrophic and anti-oxidant effect of beta3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation[J].J Mol Cell Cardiol,2013,62:8-17.
[18]Aragón JP,Condit ME,Bhushan S,et al.Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation[J].J Am Coll Cardiol,2011,58(25):2683-2691.
[19]Niu X,Watts VL,Cingolani OH,et al.Cardioprotective effect of beta-3 adrenergic receptor agonism:role of neuronal nitric oxide synthase[J].J Am Coll Cardiol,2012,59(22):1979-1987.
[20]Idigo WO,Reilly S,Zhang MH,et al.Regulation of endothelial nitric-oxide synthase (NOS) S-glutathionylation by neuronal NOS:evidence of a functional interaction between myocardial constitutive NOS isoforms[J].J Biol Chem,2012,287(52):43665-43673.
[21]Khan SA,Lee K,Minhas KM, et al.Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling[J].Proc Natl Acad Sci USA,2004,101(45):15944-15948.
[22]Ignarro LJ,Byrns RE,Trinh K,et al.Nebivolol:a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms[J].Nitric Oxide,2002,7(2):75-82.
[23]Feng MG,Prieto MC,Navar LG.Gabriel Navar.Nebivolol-induced vasodilation of renal afferent arterioles involve3-adrenergic receptor and nitric oxide synthase activation[J].Am J Physiol Renal Physiol,2012,303(5):F775-F782.
[24]Balligand JL.Beta3-adrenoreceptors in cardiovasular diseases:new roles for an“old”receptor[J].Curr Drug Deliv,2013,10(1):64-66.
[25]Vasina V,Giannone F,Domenicali M,et al.Portal hypertension and liver cirrhosis in rats: effect of the β3-adrenoceptor agonist SR58611A[J].Br J Pharmacol,2012,167(5):1137-1147.
[26]Cernecka H,Sand C,Michel MC.The odd sibling:features of β3-adrenoceptor pharmacology[J].Mol Pharmacol,2014,86(5):479-484.
[27]Kulandavelu S,Hare JM.Alterations in beta3-adrenergic cardiac innervation and nitric oxide signaling in heart failure[J].J Am Coll Cardiol,2012,59(22):1988-1990.
[28]Niu X,Zhao L,Li X,et al.beta3-adrenoreceptor stimulation protects against myocardial infarction injury via eNOS and nNOS activation[J].PLoS One,2014,9(6):e98713.
[29]Belge C,Hammond J,Dubois-Deruy E,et al.Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase[J].Circulation,2014,129(4):451-462.

备注/Memo

备注/Memo:

收稿日期：2015-10-08.
基金项目：国家自然科学基金青年项目资助（81200099）;国家自然科学基金项目资助（81570227）
通讯作者：牛晓琳，副主任医师，主要从事心力衰竭发生机制和防治研究 Email：xiaolinniu@163.com
作者简介：王彬，博士生 Email：wangbinfmmu@163.com

常用功能

更新日期/Last Update: 2016-04-13